FIELD: medicine.
SUBSTANCE: invention is related to nucleic acids and multidomain proteins, which are able to bind vessel endotheliocyte growth factor (VEGF), and may be used in medicine. Recombinant method is used to produce polypeptide, which consists of component (R1R2)X and, unnecessarily, multidomain component (MC), which represents aminoacid sequence with length from 1 to 200 of amino acids, having at least one remainder of cysteine, where X≥1, R1 means antibody-like (Ig) domain 2 of VEGF receptor Llt-1, and R2 means Ig-domain 3 of VEGF receptor Flk-1. Produced fused polypeptide does not contain multidomain component in case, when X=2, and in case when X=1, multidomain component represents aminoacid sequence with length from 1 to 15 amino acids. Produced polypeptide is used in composition of pharmaceutical compound for VEGF-mediated disease or condition.
EFFECT: invention makes it possible to produce highly efficient trap of VEGF, special structure of which is suitable for local introduction into specific organs, tissues or cells.
16 cl, 3 tbl, 7 ex
Title | Year | Author | Number |
---|---|---|---|
FUSED POLYPEPTIDE ABLE FOR BINDING WITH VEGF POLYPEPTIDE AND NUCLEIC ACID MOLECULE ENCODING THEREOF, THEIR PREPARING AND USING | 2000 |
|
RU2265661C2 |
COMPOUND ANTAGONIST VEGF AND ANTIPROLIFERATIVE AGENT | 2004 |
|
RU2353353C2 |
METHOD OF TREATING DISEASES BY VEGF ANTAGONISTS | 2006 |
|
RU2414924C2 |
FUSED POLYPEPTIDE WITH ANTICANCER ACTIVITY | 2016 |
|
RU2727165C2 |
FUSED PROTEINS CONTAINING PDGF AND VEGF BINDING PARTS, AND METHODS FOR USE THEREOF | 2014 |
|
RU2692652C2 |
COMPOSITIONS OF HUMANISED NOTCH FUSED PROTEINS AND METHODS OF TREATING | 2008 |
|
RU2532830C2 |
IMMUNOSUPPRESSIVE POLYPEPTIDES AND NUCLEIC ACIDS | 2008 |
|
RU2506275C2 |
POLYPEPTIDES BINDING TO CD3 | 2013 |
|
RU2673153C2 |
ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCTION THEREOF | 2020 |
|
RU2824045C2 |
FUSED POLYPEPTIDES AND VACCINES | 2014 |
|
RU2699006C2 |
Authors
Dates
2009-12-20—Published
2004-06-29—Filed